Efamol Active Memory was launched to complement Efalex Brain Formula to support brain health in adults. It contains high strength fish oil high in DHA with Vitamin B12, Folic Acid, Ginkgo Biloba and Phosphatidylserine. Specially formulated for adults over 40.
As we age, a few things happen to our brain chemistry and its size and structure. Our brains begin to shrink after the age of 40 at a rate of around 5% every 10 years and possibly even quicker after the age of 70. This affects our ability to think quickly and recall from short-term memory. Studies suggest that an adequate amount of DHA in the brain is important for the health of the ageing adult brain and contributes to sustained brain function as we age.
Epidemiological studies have suggested a beneficial effect of fish oil supplementation in halting the initial progression of Alzheimer’s disease. A study in 2013 found that the active DHA-rich oil in Active Memory significantly improved memory function including short term and working memory, immediate verbal memory and delayed recall memory.
Dementia and age-related macular degeneration (AMD) are major causes of disability in the elderly. n−3 Fatty acids, particularly docosahexaenoic acid (DHA), are highly concentrated in brain and retinal tissue and may prevent or delay the progression of dementia and age-related macular degeneration. Low dietary intakes and plasma concentrations have been reported to be associated with dementia, cognitive decline, and age-related macular degeneration risk.
No treatment effects were observed for the primary outcome, habitual walking speed. Improvements in verbal memory and executive function were seen for all treatments groups v.placebo (all, P < 0·05). Significant improvements in self-reported emotional well-being were seen with multi-nutrient and exercise groups v. placebo (P = 0·03). The results suggest that the high-DHA multi-nutrient supplement produces similar improvements in cognitive function to aerobic exercise, offering the intriguing prospect that supplementation may be able to mitigate some of the effects of low physical activity on cognitive function in the elderly.
Significant improvements were seen in 2 of the 4 cognitive tests, with shorter mean latencies in a motor screening task (p < .05) & more words remembered (p < .03), and 1 of the 3 primary mobility measures with improved habitual walking speed (p < .05). Compared with the placebo, supplementation also produced significantly higher blood DHA levels (p < .02). This pilot study, showed that Active Memory improved cognition and mobility in able older females at clinically relevant levels, suggesting a potential role in reducing the decline to frailty.
Prospective, randomised trial with an unsupplemented control group. This study which was the first one to use Active Memory showed improvements were greater in the Efamol Active Memory treated patients for 5 of the memory tests with the results being significantly greater for delayed prompted text recall. There was no or less deterioration in the Efamol Active Memory treated patients for 5 of the EQ 5D tests with the results for anxiety and depression being significantly less.
